Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

被引：0
|
作者：
McGregor, Bradley Alexander
Wang, Xin Victoria
Hamnvik, Ole-Petter R.
Cheung, Yee Ming
Wei, Xiao X.
Ravi, Praful
Fichorova, Raina N.
Sweeney, Christopher
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation plus enzalutamide plus/minus zoledronic acid: The BonEnza study
    Volta, A. Dalla
    Valcamonico, F.
    Zivi, A.
    Procopio, G.
    Sepe, P.
    Del Conte, G.
    Di Meo, N.
    Foti, S.
    Zamboni, S.
    Messina, C.
    Lucchini, E.
    Rizzi, A.
    Ravanelli, M.
    Caramella, I.
    Zamparini, M.
    Milella, M.
    Suardi, N.
    Maroldi, R.
    Farina, D.
    Berruti, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S965 - S965
  • [42] Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).
    Palmbos, Phillip Lee
    Tomlins, Scott A.
    Daignault, Stephanie
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia K.
    Kelly, William Kevin
    Arora, Vivek
    Antonarakis, Emmanuel S.
    Siddiqui, Javed
    Robinson, Dan
    Knudsen, Karen E.
    Chinnaiyan, Arul
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Azad, Arun
    Musto, Clark
    Netanel, Shir
    Zhang, Tian
    Rathkopf, Dana E.
    Badillo, Marco Antonio
    Dong, Qiang
    Morgans, Alicia K.
    Runcie, Karie
    Dos Santos, Alex
    Bhaumik, Amitabha
    Mundle, Suneel
    McCarthy, Sharon
    Lopez-Gitlitz, Angela Mennicke
    Batavia, Ashita S.
    Sanchez, Daniel P.
    Wildgust, Mark A.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)
    Chi, K. N.
    Chowdhury, S.
    Radziszewski, P.
    Lebret, T.
    Ozguroglu, M.
    Sternberg, C.
    Sims, R. B.
    Yu, M.
    Naini, V.
    Darif, M.
    Merseburger, A. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
    Agarwal, Neeraj
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Plets, Melissa
    Lara, Primo
    Harzstark, Andrea
    Twardowski, Przemyslaw
    Paller, Channing Judith
    Zylla, Dylan M.
    Zibelman, Matthew R.
    Levine, Ellis Glenn
    Roth, Bruce J.
    Goldkorn, Amir
    Vaena, Daniel A.
    Kohli, Manish
    Crispino, Tony
    Vogelzang, Nicholas J.
    Thompson, Ian Murchie
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] China ARCHES: A multicenter phase III randomized doubleblind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) vs PBO plus ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Zhou, F.
    Gongqian, Z.
    Guo, H.
    Hu, Z.
    Zhang, X.
    He, D.
    He, Z.
    Zhang, D.
    Li, Y.
    Kadeerbai, H.
    Liu, Y.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S971 - S971
  • [47] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
    Zhuifeng Guo
    Xuwei Lu
    Fan Yang
    Liang Qin
    Ning Yang
    Jiawen Wu
    Hang Wang
    European Journal of Medical Research, 27
  • [48] Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
    Azad, Arun
    Iguchi, Taro
    Alekseev, Boris
    Shore, Neal D.
    Sugg, Jennifer
    Haas, Gabriel P.
    Wozniak, Michele
    O'Brien, Thomas
    Laird, Douglas
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
    Guo, Zhuifeng
    Lu, Xuwei
    Yang, Fan
    Qin, Liang
    Yang, Ning
    Wu, Jiawen
    Wang, Hang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [50] BENEFIT OF ABIRATERONE ACETATE PLUS PREDNISONE (AA plus P) ADDED TO ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH HIGH-RISK, NEWLY DIAGNOSED METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Metin, H.
    McQuarrie, K.
    Thilakarathne, M.
    Diels, J.
    Ito, T.
    Li, T.
    Sulur, G.
    Chi, K. N.
    Fizazi, K.
    VALUE IN HEALTH, 2018, 21 : S38 - S38
12345